PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $182,734 | -16.6% | 5,958 | +8.8% | 0.00% | – |
Q2 2023 | $219,210 | -10.5% | 5,476 | -8.7% | 0.00% | – |
Q1 2023 | $244,833 | -59.5% | 6,000 | -61.6% | 0.00% | -100.0% |
Q4 2022 | $603,973 | -30.4% | 15,636 | -4.4% | 0.00% | -50.0% |
Q3 2022 | $868,000 | -5.9% | 16,355 | +3.5% | 0.00% | 0.0% |
Q2 2022 | $922,000 | -47.6% | 15,805 | -31.6% | 0.00% | -33.3% |
Q1 2022 | $1,761,000 | +77.3% | 23,115 | +40.2% | 0.00% | +50.0% |
Q4 2021 | $993,000 | +181.3% | 16,490 | +161.8% | 0.00% | +100.0% |
Q3 2021 | $353,000 | -0.3% | 6,299 | +8.8% | 0.00% | 0.0% |
Q2 2021 | $354,000 | -13.7% | 5,790 | -0.9% | 0.00% | 0.0% |
Q1 2021 | $410,000 | +14.2% | 5,840 | -2.4% | 0.00% | 0.0% |
Q4 2020 | $359,000 | -2.2% | 5,984 | -2.0% | 0.00% | 0.0% |
Q3 2020 | $367,000 | +56.8% | 6,106 | +35.2% | 0.00% | 0.0% |
Q2 2020 | $234,000 | +73.3% | 4,516 | +12.7% | 0.00% | 0.0% |
Q1 2020 | $135,000 | – | 4,007 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |